MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30.

Income Overview

Net Income
-$10,822K
EPS
-$2.21
Unit: Thousand (K) dollars

Income Statement
2025-09-30
Research and development
2,361
General and administrative
2,687
Total operating expense
5,048
Loss from operations
-5,048
Interest expense-Nonrelated Party
31
Interest expense-Related Party
10
Change in fair value of other liabilities and derivatives-Nonrelated Party
93
Change in fair value of other liabilities and derivatives-Related Party
7
Other income (expense), net
18
Total other income (expenses), net
-123
Loss before income taxes
-5,171
Income tax provision
10
Net loss
-5,181
Net loss attributable to noncontrolling interest
-32
Net loss attributable to controlling interest
-5,149
Deemed dividend on warrants
-5,673
Net loss attributable to common stockholders
-10,822
Basic EPS
-2.21
Diluted EPS
-2.21
Basic Average Shares
4,907
Diluted Average Shares
4,907
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Net lossattributable to common...-$10,822K Deemed dividend onwarrants-$5,673K Net lossattributable to controlling...-$5,149K Net lossattributable to...-$32K Net loss-$5,181K Loss before incometaxes-$5,171K Income tax provision$10K Loss from operations-$5,048K Total other income(expenses), net-$123K Other income(expense), net$18K Total operatingexpense$5,048K Change in fair value ofother liabilities and...$93K Interestexpense-Nonrelated Party$31K Interestexpense-Related Party$10K Change in fair value ofother liabilities and...$7K General andadministrative$2,687K Research and development$2,361K

Calidi Biotherapeutics, Inc. (CLDI)

Calidi Biotherapeutics, Inc. (CLDI)